- Home
- MRCC vs IKT Comparison
MRCC vs IKT Comparison
Compare MRCC & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCC | IKT |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.2M | 181.9M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MRCC | IKT |
|---|---|---|
| Price | $6.52 | $1.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $8.00 | $4.00 |
| AVG Volume (30 Days) | 99.0K | ★ 562.6K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | ★ 11.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.86 | $1.33 |
| 52 Week High | $8.85 | $4.20 |
Technical Indicators
Market Signals| Indicator | MRCC | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 62.92 |
| Support Level | $6.20 | $1.52 |
| Resistance Level | $6.80 | $1.73 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 56.72 | 90.18 |
Price Performance
Historical ComparisonAbout MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.